Chimeric Therapeutics Secures $1.62M Advance to Fuel Phase 1/2 Trials

Advance Funding Boosts Clinical Trial Resources

Chimeric Therapeutics (ASX:CHM) has drawn down $1.62 million from Endpoints Capital, tapping into a funding facility secured against its anticipated FY26 Research and Development Tax Incentive (RDTI). This injection is earmarked to support the company’s ongoing Phase 1/2 clinical trials and general working capital needs, providing a timely liquidity boost as Chimeric navigates a critical phase of development.

Facility Terms and Repayment Schedule

The funding arrangement allows Chimeric early access to a portion of the refundable tax offset it expects to receive from the Australian Taxation Office, with repayment due by 31 December 2026. Interest accrues at a commercial rate, and the company retains flexibility to repay the facility earlier if desired. Notably, this new facility replaces a previous R&D funding arrangement with Radium Capital, which has now been fully repaid and discharged.

Strategic Review Underway Amid Clinical Progress

Chimeric is concurrently conducting a Strategic Review aimed at unlocking shareholder value, a process that underscores the importance of maintaining access to flexible funding. The company’s pipeline features multiple clinical-stage cell therapy programs, including the CDH17 CAR T therapy and CORE-NK natural killer cell platform. Recent trial data have shown encouraging signs of efficacy and disease stability, reinforcing the potential of these assets to advance through clinical milestones.

R&D Tax Incentive as a Vital Funding Lever

The Australian Government’s RDTI program offers a refundable tax offset of up to 43.5% for eligible R&D activities, a critical support mechanism for biotech companies like Chimeric. Leveraging this incentive through financing arrangements can smooth cash flow volatility inherent in clinical development cycles, allowing companies to maintain momentum without immediate equity dilution.

What Investors Should Watch Next

With the repayment of the Radium Capital facility complete and a fresh advance secured, Chimeric is better positioned to fund its clinical programs into the latter half of 2026. Investors will be looking for updates on the outcomes of the Strategic Review and progress reports from the Phase 1/2 trials, especially as the company approaches key dosing and data readout milestones.